An official website of the United States government
Home
Name
CTL019
Alternate Names
None
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
chimeric antigen receptor T cell (CAR-T)
NSC Number
None
Primary Site
None
Histology
Diffuse large B-cell lymphoma
Remarks
4/23/2017: FDA granted Breakthrough Therapy designation to Novartis’s CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adult patients with relapsed and refractory (r/r) diffuse large B-cell lymphoma who have failed two or more prior therapies
Coding
This drug should be coded
